相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。STAT5A-Mediated SOCS2 Expression Regulates Jak2 and STAT3 Activity Following c-Src Inhibition in Head and Neck Squamous Carcinoma
Banibrata Sen et al.
CLINICAL CANCER RESEARCH (2012)
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2
A. V. Purandare et al.
LEUKEMIA (2012)
STAT3 expression in activating EGFR-driven adenocarcinoma of the lung
Saburo Takata et al.
LUNG CANCER (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways
D. B. Badgwell et al.
ONCOGENE (2012)
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells
I. Lakshmanan et al.
ONCOGENE (2012)
Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway
Miran Jo et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2012)
The JAK2 exon 12 mutations: A comprehensive review
Linda M. Scott
AMERICAN JOURNAL OF HEMATOLOGY (2011)
JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma
Katrien Van Roosbroeck et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Multiple myeloma with concomitant JAK2-positive essential thrombocythemia post-successful autologous peripheral blood hematopoietic stem cell transplant
S. G. Holtan et al.
BONE MARROW TRANSPLANTATION (2011)
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
Anne M. Traynor et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study
Jane E. Minturn et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma
Robin E. Norris et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor-Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells
Yan Liu et al.
CANCER PREVENTION RESEARCH (2011)
Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480
Hong Xin et al.
CANCER RESEARCH (2011)
STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis
Ryan B. Corcoran et al.
CANCER RESEARCH (2011)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
Loredana Santo et al.
CLINICAL CANCER RESEARCH (2011)
TG-101348 Tyrosine-Protein Kinase JAK2 Inhibitor Receptor-Type Tyrosine-Protein Kinase FLT3 Inhibitor Treatment of Myeloproliferative Diseases
Brian L. Harry et al.
DRUGS OF THE FUTURE (2011)
Janus kinase 2 inhibitors in myeloproliferative disorders
Eugenio Lucia et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
New JAK2 inhibitors for myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms
Sylvia Hoeller et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Human gastrin mRNA expression up-regulated by Helicobacter pylori CagA through MEK/ERK and JAK2-signaling pathways in gastric cancer cells
Jianjiang Zhou et al.
GASTRIC CANCER (2011)
Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia
Takayuki Ikezoe et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis
H. J. Deeg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
Anthony D. William et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells
Christian Senft et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models
Yunguang Sun et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation
Hao Liu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma
Braden C. McFarland et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival
A. Scuto et al.
LEUKEMIA (2011)
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells
K. A. Monaghan et al.
LEUKEMIA (2011)
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
S. Hart et al.
LEUKEMIA (2011)
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer
Mei Zhao et al.
LUNG CANCER (2011)
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Alfonso Quintas-Cardama et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
Daniela Ungureanu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2011)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+myeloma cells
Vijay Ramakrishnan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells
Seiichi Okabe et al.
ANNALS OF HEMATOLOGY (2010)
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Fabio P. S. Santos et al.
BLOOD (2010)
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
Libi Hertzberg et al.
BLOOD (2010)
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
Ruriko Tanaka et al.
BLOOD (2010)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
Jeffrey W. Tyner et al.
BLOOD (2010)
No evidence for JAK2 V617F mutation in colorectal cancer
M. Herreros-Villanueva et al.
BRITISH JOURNAL OF BIOMEDICAL SCIENCE (2010)
Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia
Benoite Perez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation
Ke Liang et al.
CANCER CELL (2010)
MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2
Ling Ding et al.
CELL RESEARCH (2010)
Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma
Radhika Iyer et al.
CLINICAL CANCER RESEARCH (2010)
Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells
Wei-Lun Huang et al.
MOLECULAR CANCER (2010)
Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line
Zhanzhong Shi et al.
MOLECULAR CANCER RESEARCH (2010)
AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells
Jing Yang et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Activity of the Aurora Kinase Inhibitor VX-680 against Bcr/Abl-Positive Acute Lymphoblastic Leukemias
Fei Fei et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3
Fan Yang et al.
MOLECULAR CANCER THERAPEUTICS (2010)
KRAS Mutant Lung Cancer Cells Are Differentially Responsive to MEK Inhibitor Due to AKT or STAT3 Activation: Implication for Combinatorial Approach
Young-Kwang Yoon et al.
MOLECULAR CARCINOGENESIS (2010)
Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells
T. Lasho et al.
LEUKEMIA (2010)
JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia
H. Andrikovics et al.
LEUKEMIA (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer
Lei Gu et al.
ANALYTICAL CELLULAR PATHOLOGY (2010)
Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells
Seiichi Okabe et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas
M. Colomiere et al.
BRITISH JOURNAL OF CANCER (2009)
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia
Amos Gaikwad et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
Marcello Tonelli et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat et al.
CANCER CELL (2009)
Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding
Banibrata Sen et al.
CANCER RESEARCH (2009)
Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells
Nils H. Thoennissen et al.
CANCER RESEARCH (2009)
Aurora B kinase inhibition in mitosis Strategies for optimising the use of aurora kinase inhibitors such as AT9283
Jayne Curry et al.
CELL CYCLE (2009)
Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of α6β1 integrin
Michelle Colomiere et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling
Hua Xiong et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas
Cecile Meier et al.
MODERN PATHOLOGY (2009)
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Julia Bohlius et al.
LANCET (2009)
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
A. Pardanani et al.
LEUKEMIA (2009)
Jak2 Inhibitors: Rationale and Role as Therapeutic Agents in Hematologic Malignancies
Jacqueline Sayyah et al.
CURRENT ONCOLOGY REPORTS (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Absence of JH2 domain mutation of the tyrosine kinase JAK2 in renal cell carcinomas
Jianming Zhao et al.
ACTA ONCOLOGICA (2008)
Stat3 promotes metastatic progression of prostate cancer
Junaid Abdulghani et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
Yun Dai et al.
BLOOD (2008)
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia
Gabriella Cirmena et al.
CANCER GENETICS AND CYTOGENETICS (2008)
Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth
Yvonne G. Lin et al.
CLINICAL CANCER RESEARCH (2008)
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
Yannick Arlot-Bonnemains et al.
ENDOCRINE-RELATED CANCER (2008)
Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia
Jennifer L. Poitras et al.
GENES CHROMOSOMES & CANCER (2008)
Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression
Kay-Uwe Wagner et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
Dani Bercovich et al.
LANCET (2008)
Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia
Fermin M. Sanchez-Guijo et al.
LEUKEMIA RESEARCH (2008)
JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies
William Vainchenker et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
SOCS regulation of the JAK/STAT signalling pathway
Ben A. Croker et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
V. Guerini et al.
LEUKEMIA (2008)
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia
Xue-Fei Huang et al.
BLOOD (2008)
Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms
Vesna Naifeld et al.
EXPERIMENTAL HEMATOLOGY (2007)
Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6
Anja Mottok et al.
BLOOD (2007)
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia
Sebastien Malinge et al.
BLOOD (2007)
JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia
M. Zecca et al.
LEUKEMIA (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J. Giles et al.
BLOOD (2007)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model
Thomas Mercher et al.
BLOOD (2006)
Screening of JAK2 V617F mutation in multiple myeloma
A. Fiorini et al.
LEUKEMIA (2006)
JAK signaling globally counteracts heterochromatic gene silencing
Song Shi et al.
NATURE GENETICS (2006)
Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma:: 9p23 neocentromere and 9p23∼p24 amplification including JAK2 and JMJD2C
Antoine Italiano et al.
CANCER GENETICS AND CYTOGENETICS (2006)
JAW/STAT signal transduction: Regulators and implication in hematological malignancies
L Valentino et al.
BIOCHEMICAL PHARMACOLOGY (2006)
The JAK2 V617F mutation in de novo acute myelogenous leukemias
JW Lee et al.
ONCOGENE (2006)
Absence of JAK2 V617F mutation in gastric cancers
JW Lee et al.
ACTA ONCOLOGICA (2006)
A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma
J Adélaïde et al.
LEUKEMIA (2006)
JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas
JW Lee et al.
LEUKEMIA & LYMPHOMA (2006)
Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia
CP Kratz et al.
LEUKEMIA (2006)
Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas
TL Lee et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma
I Melzner et al.
LEUKEMIA (2006)
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia
J Jelinek et al.
BLOOD (2005)
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene
M Bousquet et al.
ONCOGENE (2005)
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q 11.2) translocation in a patient with a clinically typical chronic myeloid leukemia
F Griesinger et al.
GENES CHROMOSOMES & CANCER (2005)
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders
LM Scott et al.
BLOOD (2005)
JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia
C Tono et al.
LEUKEMIA (2005)
Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma
Y Niwa et al.
ONCOGENE (2005)
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma
SY Lai et al.
ONCOGENE (2005)
Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma
A Mohyeldin et al.
NEOPLASIA (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
A Reiter et al.
CANCER RESEARCH (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line
I Melzner et al.
BLOOD (2005)
IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells
KT Chang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation
A Murati et al.
LEUKEMIA (2005)
The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia
S Sulong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
EA Harrington et al.
NATURE MEDICINE (2004)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer
A Scholz et al.
GASTROENTEROLOGY (2003)
Inhibitors that target protein kinases for the treatment of ovarian carcinoma
R Arbel et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2003)
Janus kinases: components of multiple signaling pathways
SG Rane et al.
ONCOGENE (2000)
分享论文
